Whitepapers

In this paper, we aim to define the different types of burden of illness studies and highlight the importance of qualitative burden of illness studies as complementary to patient reported outcomes data, and as separate stand-alone research projects that can further support HTA committees in their decision-making.

Therapies designed to target cancers with specific molecular signatures have reshaped the landscape of oncological drug development.1 As the next generation of tumor-agnostic therapies make their way through clinical trials, we should be asking ourselves what we can do to prepare for the upcoming challenge of reimbursement in this space, and what lessons can be learnt from the experience of existing therapies. Over the coming months we will provide recommendations from our own experience and a review of the experiences of the tropomyosin receptor kinase (TRK) inhibitors (larotrectinib and entrectinib) on how to overcome the common challenges in this space in five short papers. Here, we look at what to consider when developing economic models of tumor-agnostic therapies, with a particular focus on the role of genetic testing in this space.

Payers have influence at a number of points across a brand's lifecycle. Understanding and managing the impact of this influence is key to unlocking an intervention's commercial potential. We've created a roadmap that outlines the different stages that payers can influence and outlines strategic considerations for brand teams.